Replies to post #5934 on Cellectar Biosciences Inc (CLRB)

[Cshom67]

Agree with you - high risk here, so people will want to get out...

Just opening the Ph2 is not necessarily a value driver for me. They had a Ph2 before and that didn't help them much.
I am wondering how they will be enrolling and dosing patients this month (acc'd to their milestones) for the Ph2 while they are still evaluating dose levels in the Ph1. Opening cohort 4 was spun as great news, but in reality it may be pushing out there Ph2 now as they have uncertainty about the starting dose level.